LATEST

• BUSINESS Astellas, MSD File Padcev-Keytruda for Cisplatin-Eligible MIBC in Japan
  May 15, 2026

• REGULATORY Japan to Launch CEA “Technical Discussions” under MHLW Research Group
  May 14, 2026

• REGULATORY Mounjaro Hit with 25% Price Cut under Japan’s “SPA-SSS” Re-Pricing
  May 14, 2026

• REGULATORY Japan OKs Listing of Ambelvist, Dojolvi, Sohonos, and Finally Inrebic
  May 14, 2026

• REGULATORY Chuikyo Clears NHI Listing for Amchepry, Akuugo, and Zolgensma Intrathecal
  May 14, 2026

• BUSINESS Sumitomo Notches Record Profit on Strong North America Growth
  May 14, 2026

• BUSINESS Takeda’s FY2025 Sales Fall 1.7% on Vyvanse Generic Erosion
  May 14, 2026

• REGULATORY Tepezza, Trodelvy Headed for NHI Price Cuts after CEAs
  May 14, 2026

• REGULATORY Briviact Faces 4.3% Price Cut from August under CEA Scheme
  May 14, 2026

• REGULATORY Chuikyo to Apply Drug Pricing Rules to Ferring’s Adstiladrin
  May 14, 2026

• REGULATORY Japan to Finalize 1st ALS Trial Guidelines This Year to Spur Global Development
  May 13, 2026

• REGULATORY Biosimilar Efficacy Trials Can Be Waived under Certain Conditions: MHLW
  May 13, 2026

• BUSINESS Shionogi Nets 4th Straight Year of Record Earnings on Torii Deal, HIV Royalties
  May 13, 2026

• BUSINESS Santen’s Eylea Sales Fall 15.9% amid Re-Pricing, Biosimilar Entry
  May 13, 2026

• BUSINESS Fuji’s Eylea Biosimilar Logs 776 Million Yen in First 3 Months
  May 13, 2026

• BUSINESS Japan Ethical Drug Sales Climb 9.3% in March: Crecon
  May 13, 2026

• REGULATORY LDP Lawmakers’ League Eyes Broader Push for Domestic API Production
  May 13, 2026

• BUSINESS Daiichi Targets 3 Trillion Yen Sales by FY2030, Global Top-5 Oncology Spot
  May 12, 2026

• BUSINESS Lilly Japan Hits Record Sales as Mounjaro Tops 100 Billion Yen
  May 12, 2026

• REGULATORY AstraZeneca’s Oral SERD, MSD RSV Antibody Up for Japan Panel Review on May 25
  May 12, 2026

ページ

• « 先頭
• ‹ Prev
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »